Literature DB >> 8929866

Activation of circulating polymorphonuclear leukocytes in preterm infants with severe idiopathic respiratory distress syndrome.

F Brus1, W van Oeveren, A Okken, S O Bambang.   

Abstract

We have studied activation of circulating polymorphonuclear leukocytes (PMN) in plasma of preterm infants with severe idiopathic respiratory distress syndrome (IRDS group, n = 15) and without IRDS (reference group, n = 15) during the first 5 postnatal days. We have observed lower median PMN counts in the IRDS group than in the reference group from d 2 (1.4 x 10(9)/L versus 4.8 x 10(9)/L in the reference group, p < 0.001) to d 4 to 6 (1.6 x 10(9)/L versus 4.0 x 10(9)/L, p < 0.01). Lower PMN counts in the IRDS infants were accompanied by lower median plasma elastase-alpha1-proteinase inhibitor (PI) concentrations (53.6 ng/mL versus 128.0 ng/mL in the reference group on d 2, p < 0.05). Simultaneously, median elastase-alpha1-PI/PMN ratios of these infants were significantly higher (40.8 ng/10(6) PMN versus 21.8 ng/10(6) PMN on d 2, p < 0.05), indicating activation of circulating PMN. Activation of circulating PMN in the IRDS group is associated with platelet-activating factor (PAF) release and complement activation from within 6 to 12 h of birth but not with release of tumor necrosis factor-alpha. PAF release was represented by significantly reduced inhibiting capacity (58% of normal human plasma, p < 0.01) and complement activation by higher median plasma C3a des-Arg concentrations (1680 ng/mL versus 325 ng/mL in the reference group, p < 0.001). We conclude that circulating PMN are activated in preterm infants with severe IRDS, which might be caused by systemic PAF release and complement activation. This activation process may play a role in the pathogenesis of the IRDS by influx of activated PMN into the lungs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8929866     DOI: 10.1203/00006450-199603000-00013

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

Review 1.  A risk-benefit assessment of drugs used for neonatal chronic lung disease.

Authors:  D G Sweet; H L Halliday
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

2.  Type I collagenases in bronchoalveolar lavage fluid from preterm babies at risk of developing chronic lung disease.

Authors:  D G Sweet; K J McMahon; A E Curley; C M O'Connor; H L Halliday
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-05       Impact factor: 5.747

3.  Mechanisms underlying reduced responsiveness of neonatal neutrophils to distinct chemoattractants.

Authors:  B Weinberger; D L Laskin; T M Mariano; V R Sunil; C J DeCoste; D E Heck; C R Gardner; J D Laskin
Journal:  J Leukoc Biol       Date:  2001-12       Impact factor: 4.962

4.  Heart rate and leukocytes after air and ground transportation in artificially ventilated neonates: a prospective observational study.

Authors:  Stefan Grosek; Gorazd Mlakar; Ivan Vidmar; Alojz Ihan; Janez Primozic
Journal:  Intensive Care Med       Date:  2008-09-13       Impact factor: 17.440

5.  In-vitro activation of complement system by lactic acidosis in newborn and adults.

Authors:  F Hecke; T Hoehn; E Strauss; M Obladen; J Sonntag
Journal:  Mediators Inflamm       Date:  2001-02       Impact factor: 4.711

6.  Deleted in Malignant Brain Tumors 1 (DMBT1) is present in hyaline membranes and modulates surface tension of surfactant.

Authors:  Hanna Müller; Caroline End; Marcus Renner; Burkhard M Helmke; Nikolaus Gassler; Christel Weiss; Dominik Hartl; Matthias Griese; Mathias Hafner; Annemarie Poustka; Jan Mollenhauer; Johannes Poeschl
Journal:  Respir Res       Date:  2007-10-01

7.  Acidosis activates complement system in vitro.

Authors:  M Emeis; J Sonntag; C Willam; E Strauss; M M Walka; M Obladen
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.